Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection

Infection and Immunity

Volumn 65, Issue 12, 1997, Pages 4996-5002

  Ghiara, Paolo ^a   Rossi, Michela ^a   Marchetti, Marta ^a   Di Tommaso, Annalisa ^a   Vindigni, Carla ^b   Ciampolini, Fabrizio ^c   Covacci, Antonello ^a   Telford, John L ^a   De Magistris, Maria Teresa ^a   Pizza, Mariagrazia ^a   Rappuoli, Rino ^a   Del Giudice, Giuseppe ^a  

^a CHIRON VACCINES   (Italy)

^b Inst of Pathol Anat and Histology   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GASTROINTESTINAL MUCOSA; HELICOBACTER PYLORI; IMMUNOSTIMULATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REINFECTION; VACCINATION;

EID: 0030728943     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.12.4996-5002.1997     Document Type: Article

References (48)

1. Atherton, J. C., P. Cao, R. M. Peek, M. K. R. Tummuru, M. J. Blaser, and T. L. Cover. 1995. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori - association of specific vacA types with cytotoxin production and peptic ulceration. J. Biol. Chem. 270:17771-17777.
2. Blaser, M. J., and J. Parsonnet. 1994. Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J. Clin. Invest. 94:4-8.
3. Blaser, M. J., G. I. Perez-Perez, H. Kleanthous, T. L. Cover, R. M. Peek, P. H. Chyou, G. N. Stemmermann, and A. Nomura. 1995. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 55:2111-2115.
4. Censini, S., C. Lange, Z. Y. Xiang, J. E. Crabtree, P. Ghiara, M. Borodovsky, R. Rappuoli, and A. Covacci. 1996. cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc. Natl. Acad. Sci. USA 93:14648-14653.
5. Chen, M., A. Lee, and S. Hazell. 1992. Immunisation against gastric helicobacter infection in a mouse/Helicobacter felis model. Lancet 339:1120-1121.
6. Corthesy-Théulaz, I., N. Porta, M. Glauser, E. Saraga, A. C. Vaney, R. Haas, J. P. Kraehenbuhl, A. L. Blum, and P. Michetti. 1995. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 109:115-121.
7. Covacci, A., S. Falkow, D. E. Berg, and R. Rappuoli. 1997. Did the inheritance of a pathogenicity island modify the virulence of Helicobacter pylori? Trends Microbiol. 5:205-208.
8. Covacci, A., S. Censini, M. Bugnoli, R. Petracca, D. Burroni, G. Macchia, A. Massone, E. Papini, Z. Xiang, N. Figura, and R. Rappuoli. 1993. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc. Natl. Acad. Sci. USA 90:5791-5795.
9. Cover, T. L., M. K. R. Tummuru, P. Cao, S. A. Thompson, and M. J. Blaser. 1994. Divergence of genetic sequences for the vacuolating cytotoxin among Helicobacter pylori strains. J. Biol. Chem. 269:10566-10573.
10. Cuenca, R., T. G. Blanchard, S. J. Czinn, J. G. Nedrud, T. P. Monath, C. K. Lee, and R. W. Redline. 1996. Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology 110:1770-1775.
11. D'Elios, M. M., M. Manghetti, M. DeCarli, F. Costa, C. T. Baldari, D. Burroni, J. L. Telford, S. Romagnani, and G. Del Prete. 1997. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J. Immunol. 158:962-967.
12. Di Tommaso, A., G. Saletti, M. Pizza, R. Rappuoli, G. Dougan, S. Abrignani, G. Douce, and M. T. De Magistris. 1996. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 64:974-979.
13. Doidge, C., I. Gust, A. Lee, F. Buck, S. Hazell, and U. Manne. 1994. Therapeutic immunisation against Helicobacter infection. Lancet 343:914-915.
14. Douce, G., M. Fontana, M. Pizza, R. Rappuoli, and G. Dougan. 1997. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin Infect. Immun. 65:2821-2828.
15. Eck, M., B. Schmausser, R. Haas, A. Greiner, S. Czub, and H. K. Muller- Hermelink. 1997. MALT-type lymphoma of the stomach is associated with Helicobacter pylori strains expressing the CagA protein. Gastroenterology 112:1482-1486.
16. Ferrero, R. L., J. M. Thiberge, M. Huerre, and A. Labigne. 1994. Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection. Infect. Immun. 62:4981-4989.
17. Ferrero, R. L., J. M. Thiberge, T. Kansau, N. Wusher, M. Huerre, and A. Labigne. 1995. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc. Natl. Acad. Sci. USA 92:6499-6503.
18. Figura, N. 1996. Mouth-to-mouth resuscitation and Helicobacter pylori infection. Lancet 347:1342.
19. Ghiara, P., M. Marchetti, M. J. Blaser, M. K. R. Tummuru, T. L. Cover, E. D. Segal, L. S. Tompkins, and R. Rappuoli. 1995. Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infect. Immun. 63:4154-4160.
20. Goddard, A. F., and R. P. H. Logan. 1996. Antimicrobial resistance and Helicobacter pylori. J. Antimicrob. Chemother. 37:639-643.
21. Haeberle, H. A., M. Rubin, K. B. Bamford, R. Garofalo, D. Y. Graham, F. El-Zaatari, R. Karttunen, S. E. Crowe, V. E. Reeys, and P. B. Ernst. 1997. Differential stimulation of interleukin-12 (IL-12) and IL-10 by live and killed Helicobacter pylori in vitro and association of IL-12 production with gamma interferon-producing T cells in human gastric mucosa. Infect. Immun. 65:4229-4235.
22. Harris, P. R., T. L. Cover, D. R. Crowe, J. M. Orenstein, M. F. Graham, M. J. Blaser, and P. D. Smith. 1996. Helicobacter pylori cytotoxin induces vacuolation of primary human mucosal epithelial cells. Infect. Immun. 64:4867-4871.
23. Lee, A., J. O'Rourke, M. C. DeUngria, B. Robertson, G. Daskalopoulos, and M. F. Dixon. 1997. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 112:1386-1397.
24. Lee, C. K., R. Weltzin, W. D. Thomas, H. Kleanthous, T. H. Ermak, G. Soman, J. E. Hill, S. K. Ackerman, and T. P. Monath. 1995. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J. Infect. Dis. 172:161-172.
25. Malfertheiner, P. 1993. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand. J. Gastroenterol. 196(Suppl.):34-37.
26. Manetti, R., P. Massari, D. Burroni, M. De Bernard, A. Marchini, R. Olivieri, E. Papini, C. Montecucco, R. Rappuoli, and J. L. Telford. 1995. Helicobacter pylori cytotoxin: importance of native conformation for induction of neutralizing antibodies. Infect. Immun. 63:4476-4480.
27. Marchetti, M., B. Aricò, D. Burroni, N. Figura, R. Rappuoli, and P. Ghiara. 1995. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 267:1655-1658.
28. Marchetti, M., M. Rossi, V. Giannelli, M. M. Giuliani, M. Pizza, S. Censini, A. Covacci, P. Massari, C. Pagliaccia, R. Manetti, J. L. Telford, G. Douce, G. Dougan, R. Rappuoli, and P. Ghiara. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a nontoxic mutant of E. coli heat labile enterotoxin (LT) as adjuvant. Vaccine, in press.
29. Marinaro, M., H. F. Staats, T. Hiroi, R. J. Jackson, M. Coste, P. N. Boyaka, N. Okahashi, M. Yamamoto, H. Kiyono, H. Bluethmann, K. Fujiashi, and J. R. McGhee. 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155:4621-4629.
30. McColm, A. A., J. Bagshaw, J. Wallis, and A. McLaren. 1995. Screening of anti-Helicobacter therapies in mice colonized with H. pylori. Gut 37(Suppl. 1):A92.
31. Michetti, P., I. Corthesy-Theulaz, C. Davin, R. Haas, A. C. Vaney, M. Heitz, J. Bille, J. P. Kraehenbuhl, E. Saraga, and A. L. Blum. 1994. Immunization of BALB/c mice against Helicobacter felis infection with H. pylori urease. Gastroenterology 107:1002-1011.
32. Mohammadi, M., S. Czinn, R. Redline, and J. Nedrud. 1996. Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice. J. Immunol. 156:4729-4738.
33. Mohammadi, M., R. Redline, J. Nedrud, and S. Czinn. 1996. Role of the host in pathogenesis of Helicobacter-associated gastritis: H. felis infection of inbred and congenic mouse strains. Infect. Immun. 64:238-245.
34. Parsonnet, J., G. D. Friedman, D. P. Vandersteen, Y. Chang, J. H. Vogelman, N. Orentreich, and R. K. Sibley. 1991. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325:1127-1231.
35. Parsonnet, J., S. Hansen, L. Rodriguez, A. B. Gelb, R. A. Warnke, E. Jellum, N. Orentreich, J. H. Vogelman, and G. D. Fried́man. 1994. Helicobacter pylori infection and gastric lymphoma. N. Engl. J. Med. 330:1267-1271.
36. Pizza, M., M. R. Fontana, M. M. Giuliani, M. Domenighini, C. Magagnoli, V. Gianelli, D. Nucci, W. Hol, R. Manetti, and R. Rappuoli. 1994. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J. Exp. Med. 80:2147-2153.
37. Ricci, V., C. Ciacci, R. Zarrilli, P. Sommi, M. K. R. Tummuru, C. D. Blanco, C. B. Bruni, T. L. Cover, M. J. Blaser, and M. Romano. 1996. Effect of Helicobacter pylori on gastric epithelial cell migration and proliferation in vitro: role of VacA and CagA. Infect. Immun. 64:2829-2833.
38. Sakagami, T., M. Dixon, J. O'Rourke, R. Howlett, F. Alderuccio, J. Vella, T. Shimoyama, and A. Lee. 1996. Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut 39:639-648.
39. Schutze, K., E. Hentschel, B. Dragosics, and A. M. Hirschl. 1995. Helicobacter pylori reinfection with identical organisms: transmission by the patients' spouses. Gut 36:831-833.
40. Takahashi, I., M. Marinaro, H. Kiyono, R. J. Jackson, I. Nakagawa, K. Fujihashi, S. Hamada, J. D. Clements, K. L. Bost, and J. R. McGhee. 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile toxin. J. Infect. Dis. 173:627-635.
41. Telford, J. L., A. Covacci, P. Ghiara, C. Montecucco, and R. Rappuoli. 1994. Unraveling the pathogenic role at Helicobacter pylori in peptic ulcer: potential for new therapies and vaccines. Trends Biotechnol. 12:420-426.
42. Telford, J. L., P. Ghiara, M. Dell'Orco, M. Comanducci, D. Burroni, M. Bugnoli, M. F. Tecce, S. Censini, A. Covacci, Z. Y. Xiang, E. Papini, C. Montecucco, L. Parente, and R. Rappuoli. 1994. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J. Exp. Med. 179:1653-1658.
43. Tummuru, M. K., T. L. Cover, and M. J. Blaser. 1993. Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production. Infect. Immun. 61:1799-1809.
44. Tytgat, G. N. J. 1996. Current indications for Helicobacter pylori eradication therapy. Scand. J. Gastroenterol. 31:70-73.
45. Tytgat, G. N. J. 1997. Antimicrobial therapy for Helicobacter pylori infection. Helicobacteriology 2(SuppI. 1):S81-S88.
46. Weel, J. F. L., R. W. M. Vanderhulst, Y. Gerrits, P. Roorda, M. Feller, J. Dankert, G. N. J. Tytgat, and A. Vanderende. 1996. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J. Infect. Dis. 173:1171-1175.
47. Xiang, Z. Y., S. Censini, P. F. Bayeli, J. L. Telford, N. Figura, R. Rappuoli, and A. Covacci. 1995. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect. Immun. 63:94-98.
48. Yamamoto, S., H. Kiyono, M. Yamamoto, K. Imaoka, K. Fujihashi, F. W. Van Ginkel, M. Noda, Y. Takeda, and J. R. McGhee. 1997. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. USA 94:5267-5272.